Shoreline Biosciences, Inc. today announced that company management will present at the Wells Fargo 2021 Virtual Healthcare Conference, September 9 -10, 2021, and the H.C. Wainwright 23rd Annual Global Investment Conference, September 13 – 15, 2021.
| SAN DIEGO, Sept. 8, 2021 /PRNewswire/ -- Shoreline Biosciences, Inc., (Shoreline), a biotechnology company developing intelligently designed allogeneic off-the-shelf, standardized, and targeted induced pluripotent stem cells (iPSC) derived natural killer (NK) and Macrophage cellular immunotherapies, today announced that company management will present and be available for one-on-one meetings at the Wells Fargo 2021 Virtual Healthcare Conference, September 9 -10, 2021, and the H.C. Wainwright 23rd Annual Global Investment Conference, September 13 – 15, 2021. Details on the presentations can be found below. Wells Fargo 2021 Virtual Healthcare Conference H.C. Wainwright 23rd Annual Global Investment Conference About Shoreline Biosciences Shoreline is dedicated to creating next-generation cellular immunotherapies for cancer and inflammatory diseases that overcome the current limitations of first-generation cell therapy products. Shoreline is building a pipeline of natural killer (NK) cell and macrophage-cell therapy candidates derived from its deep expertise in iPSC differentiation methods and genetic reprogramming of disease relevant pathways. Shoreline has strategic partnerships with Kite, a Gilead Company, and BeiGene, a global biotechnology company, and is supported by high-quality institutional investors. Shoreline Biosciences is headquartered in San Diego, CA. For more information, please visit https://shorelinebio.com/ and engage with us on LinkedIn. Shoreline Biosciences Investor and Media Contact: Amy Conrad
SOURCE Shoreline Biosciences, Inc. |
View original content to download multimedia:
